Capricor Therapeutics Announces FDA's Committee Votes That Available Evidence For Deramiocel Did Not Support Effectiveness To Treat Cardiomyopathy In Patients With Duchenne Muscular Dystrophy
Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced that the U.S. Food and Drug Administration's Cellular,
A government health committee said that Capricor's medicine didn't show it actually works for a serious muscle disease. When a company's medicine doesn't get approved, it's a setback, so investors watch carefully to see what the company does next.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.